16:39 , Mar 27, 2018 |  BC Extra  |  Preclinical News

Baylor team suggests new way to attack triple-negative breast cancer

In a paper published in Nature Medicine , researchers from Baylor College of Medicine and colleagues suggest that specifically targeting multiple RTKs regulated by protein tyrosine phosphatase non-receptor type 12 (PTPN12), a tumor suppressor frequently...
20:50 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3 . Screening of deubiquitinating enzyme...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Crenolanib regulatory update

Arog said FDA granted Fast Track designation to crenolanib besylate to treat unresectable or metastatic gastrointestinal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) D824V mutation. Crenolanib besylate is in Phase III testing...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Aflibercept/rinucumab: Phase II data

Top-line data from the double-blind, U.S. and Japanese Phase II CAPELLA trial in about 500 patients with wet AMD showed that intravitreal injections of 2/1 mg and 2/3 mg REGN2176-3 aflibercept/rinucumab every 4 weeks each...
07:00 , Sep 30, 2016 |  BC Extra  |  Clinical News

Regeneron combo fails to top Eylea alone in AMD study

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) said intravitreal injections of REGN2176-3 missed the primary endpoint in the ongoing Phase II CAPELLA study to treat wet age-related macular degeneration. The therapy, which combines the company's ophthalmic...
01:35 , May 3, 2016 |  BC Extra  |  Financial News

Ophthalmic play Graybug raises $44.5M

Graybug Vision Inc. (Redwood City, Calif.) raised $44.5 million in a series B round led by new investor Deerfield. New investors OrbiMed Advisors and Clarus Ventures also participated, along with existing investor Hatteras Venture Partners....
00:45 , Mar 25, 2016 |  BC Extra  |  Company News

Regeneron, Bayer strike another Eylea combo deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) granted Bayer AG (Xetra:BAYN) exclusive ex-U.S. rights to a combination including Regeneron's nesvacumab ( REGN910 ) and its ophthalmic drug Eylea aflibercept ophthalmic solution . The combination, formulated as a single...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Studies in mice and human samples suggest inhibiting PDGFRB could help prevent pancreatic cancer...
07:00 , May 8, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma EPH receptor B4 (EPHB4); platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B) Patient sample and mouse studies suggest inhibiting PDGFRB cross talk with...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Regeneron, Bayer deal

Regeneron and Bayer partnered to develop Regeneron's antibody against platelet derived growth factor receptor B ( PDGFRB ; PDGFR1 ; CD140B ) as a combination therapy with the partners' Eylea aflibercept to treat wet age-related...